Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance

By
Justin.choi
-
0
127
Researchers leveraged human epidermal-growth-factor receptor-2 (HER2) overexpression to engage antibody-dependent cellular phagocytosis through a combination of trastuzumab and anti-CD47 macrophage checkpoint immunotherapy.
[Proceedings of the National Academy of Sciences of the United States of America]
Full Article